NCT02378701
Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease
Phase: N/A
Role: Collaborator
Start: Feb 28, 2015
Completion: Jul 18, 2022